Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

UHGWW vs ABVC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVC Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–1 Matrix Metrics)

ABVC Overall Winner 6-Pillar Tally: UHGWW 1 – 3 ABVC (2 Tie) Matrix Metrics: UHGWW 1 – 6 ABVC

As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over United Homes Group, Inc. Warrant (UHGWW) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). UHGWW carries a Unified Composite Score of 51.6/100 (HOLD) at $0.23 (N/M Forward P/E, N/A operating margin), whereas ABVC carries 47.4/100 (HOLD) at $0.87 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While UHGWW currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. ABVC 47.4/100 HOLD), ABVC captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+104.5% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UHGWW vs ABVC
UHGWW NASDAQ
United Homes Group, Inc. Warrant
Operative Builders
$0.23
+28.13% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.85β · 112% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 63
RSI-14: 63.5 · SMA20: $0.18 · SMA50: $0.24
ABVC NASDAQ Head-to-Head Winner
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.87
-1.56% 1D
Market Cap $23.9M
TTM Revenue $797,916
Forward P/E N/M
Beta / 30D Vol 1.24β · 44% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 43.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.2 · SMA20: $0.98 · SMA50: $1.01

6-Pillar Scorecard Institutional Category Breakdown (UHGWW 1 – 3 ABVC)

Columns: Metric · UHGWW · ABVC
1. Valuation Multiples ABVC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 29.9x
2. Growth & Scale ABVC
Revenue Growth (YoY) N/A +104.5%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $797,916
Market Cap N/A $23.9M
3. Profitability & Quality ABVC
Gross Margin N/A 100.0%
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -52.7%
4. Balance Sheet & Cash Flow UHGWW
Cash Generation (TTM) N/A -$5.8M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $0.50 Book/Sh · -52.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Operative Builders Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UHGWW (1) vs ABVC (6)
Institutional Metric UHGWW ABVC Criterion Row Edge
Market Capitalization
Scale
N/A $23.9M Larger Scale ABVC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +104.5% Higher Growth ABVC
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin ABVC
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ABVC
Return on Equity (ROE)
Capital Efficiency
N/A -52.7% Higher ROE ABVC
52-Week Range Position
Momentum
7% ($0–$2) 7% ($1–$3) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.85β · 112% Vol 1.24β · 44% Vol Lower Realized Risk ABVC
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 47.4 / 100 (HOLD) Higher Composite UHGWW
Trailing 12M Revenue (USD)
Operating Scale
N/A $797,916 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 29.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$5.8M EBITDA ($0.50 Book/Sh · -52.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UHGWW +52.6 pp
UHGWW: +37.03% · ABVC: -15.57%
3M Horizon UHGWW +27.38 pp
UHGWW: -28.79% · ABVC: -56.17%
6M Horizon UHGWW +196.28 pp
UHGWW: +135.0% · ABVC: -61.28%
1Y Horizon UHGWW +196.28 pp
UHGWW: +135.0% · ABVC: -61.28%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UHGWW vs ABVC. Trailing 12-month operating profitability (UHGWW N/A vs ABVC 0.0%) and valuation multiples (UHGWW N/M vs ABVC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

UHGWW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABVC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$797,916
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-52.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UHGWW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UHGWW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UHGWW Moat Profile Cyclical / Execution-Driven Positioning
Operative Builders Operator
Competes within the Operative Builders value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $23.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ UHGWW vs ABVC Key Questions & Quantitative Answers

As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over United Homes Group, Inc. Warrant (UHGWW) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). UHGWW carries a Unified Composite Score of 51.6/100 (HOLD) at $0.23 (N/M Forward P/E, N/A operating margin), whereas ABVC carries 47.4/100 (HOLD) at $0.87 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While UHGWW currently prints a higher short-term Unified Composite Score (51.6/100 HOLD vs. ABVC 47.4/100 HOLD), ABVC captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+104.5% vs. N/A YoY).

ABVC leads the Growth & Scale pillar: UHGWW posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABVC at +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, UHGWW generates N/A in USD-normalized revenue versus $797,916 for ABVC. In operating R&D and SG&A reinvestment, UHGWW deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVC.

ABVC screens cheaper on headline valuation multiples. UHGWW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UHGWW (N/A ROE) versus ABVC (-52.7% ROE) capital efficiency.

In options market volatility and institutional positioning, UHGWW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.85β · 112% Vol realized risk). By comparison, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.24β · 44% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.